Artiva Biotherapeutics
PublicArtiva Biotherapeutics is now publicly traded
The data on this page reflects Artiva Biotherapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jul 18, 2024
Last Round
Follow-on Offering
May 8, 2026
Est. Valuation at Exit
$563.2M
Total Funding Raised
$673M
Company Overview
Artiva Biotherapeutics is a clinical-stage biotechnology company that develops off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of autoimmune diseases and cancers.
Sector
Biotech
AI Layer
Non-AI
Keywords
Artiva Biotherapeutics Comparables
Compare Artiva Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shoreline Biosciences | 82% | |
| Therabest | 81% | |
| HebeCell | 81% |
Artiva Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | May 8, 2026 | ||||
| IPO | Jul 18, 2024 | ||||
| Series B | Feb 26, 2021 | ||||
| Series A | Jun 26, 2020 | ||||
| Seed | Mar 1, 2019 |
Artiva Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B, Follow-on Offering |
| Jefferies | Follow-on Offering, IPO |
| Surveyor Capital | Series B |
| Janus Henderson Group | Series B |
| RA Capital Management | Series B, Follow-on Offering, Series A |
| Cormorant Asset Management | Series B |
| Franklin Templeton | Series B |
Artiva Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access